Guidelines on NSTE-ACS (version 2015) - Task Force · Guidelines on NSTE-ACS (version 2015) - Task...

Andreotti Felicita A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer (see also BMS) : apixaban (2012-2013)

- BMS-Pfizer : apixaban, cardiovascular metabolism (2012-2013)

- Bayer Schering Pharma : aspirin, rivaroxaban (2012-2013-2014)

- Eli Lilly : prasugrel (2012-2013-2014)

- Amgen : dyslipidemia (2012-2013-2014-2015)

- Daiichi Sankyo : edoxaban (2012-2014)

- Daiichi Sankyo-Eli Lilly : edoxaban, prasugrel (2013)

- Pfizer : apixaban (2014)

- BMS : apixaban, cardiovascular metabolism (2014)

- Bayer Schering Pharma : aspirin (2015)

- Boehringer-Ingelheim : non-vitamin k antagonist oral anticoagulants (2015)

- Daiichi Sankyo : non-vitamin k antagonist oral anticoagulants (2015)

- Pfizer : non-vitamin k antagonist oral anticoagulants (2015)

- BMS-Pfizer : non-vitamin k antagonist oral anticoagulants (2015)

Bax Jeroen Nothing to be declared (2014-2015)

D - Research funding (departmental or institutional).- Servier : Farma (2012-2013)

- Edwards Lifesciences : Heart Valves (2012-2013)

- GE Healthcare : Imaging (2012-2013)

- Lantheus Inc : Imaging (2012-2013)

- Boston Scientific : Pacing (2012-2013)

- Medtronic : Pacing (2012-2013)

27/08/2015

Guidelines on NSTE-ACS (version 2015) - Task Force

Expert Type of Relationship with Industry

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

1/50

Bax Jeroen - St Jude Medical : Pacing (2012-2013)

- Biotronik : Pacing (2012-2013)

Borger Michael A A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Edwards Lifesciences : heart valve therapy (2012-2013-2014-2015)

- St. Jude Medical : heart valve therapy (2012-2013-2014-2015)

- Medtronic : heart valve therapy (2012-2013-2015)

- Sorin Group : heart valve therapy (2013-2014-2015)

D - Research funding (departmental or institutional).- Edwards Lifesciences : heart valve therapy (2015)

Brotons Carlos A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Apixaban (2012-2013-2014-2015)

- Bayer : Aspirin (2012-2013-2014-2015)

- Astra Zeneca : Brilinta (2014)

- Lundbeck : Selincro (2014-2015)

Chew Derek B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Anti-platelet therapy (2012-2013)

- Abbott Vascular : Mitral Clip (2012-2013)

- Astra Zeneca : Antiplatelet therapy (2014-2015)

- Medscape : Physician Education (2014-2015)

D - Research funding (departmental or institutional).- Astra Zeneca : Anti-platelet therapy (2012-2013)

- Astra Zeneca : Antiplatelet (2014-2015)

Collet Jean-Philippe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : antiplatelet (2012)

- Eli Lilly : antiplatelet (2012)

- Medco Health Solutions : antiplatelet (2012)

27/08/2015




2/50

Collet Jean-Philippe - Accumetrics : antiplatelet agents (2012)

- Bristol Myers Squibb : antiplatelet and anticoagulant (2012)

- Medtronic : valves (2012)

- Bristol Myers Squibb : apixaban (2013-2014-2015)

- Eli Lilly : prasugrel (2013-2014-2015)

- Bayer : rivaroxaban (2013-2014-2015)

- Daiichi Sankyo : EDOXABAN (2014-2015)

- Astra Zeneca : TICAGRELOR (2014-2015)

D - Research funding (departmental or institutional).- Eli Lilly : prasugrel (2013)

- Bristol Myers Squibb : apixaban (2013-2014-2015)

- Medtronic : COREVALVE (2014-2015)

Gencer Baris Nothing to be declared (2012-2013-2014-2015)

Hasenfuss Gerd A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- CVRx : Baroreceptor stimulator (2012)

- Servier : Ivabradine, RYCALS (2012-2013-2014-2015)

- Impulse Dynamics : Optimizer (2012-2013-2014-2015)

- Novartis : serelaxine (2012-2013-2014-2015)

- Circulite : Assist device (2013-2014-2015)

- DC Devices : REDUC ELAP device trial (2013-2014-2015)

- Astrazeneca : Therapeutic (2013-2014-2015)

- Bayer : Xarelta (2013-2014-2015)

- CVRx : Baroreceptor Stimulation (2015)

27/08/2015




3/50

Hasenfuss Gerd B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Circulite : Assist Device (2012)

- Astra Zeneca : Brilique (2012)

- Bayer : rivaroxaban (2012)

D - Research funding (departmental or institutional).- Servier : RYCALS (2012)

Kjeldsen Keld Per Nothing to be declared (2012-2013-2014-2015)

Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boston Scientific : Heart Failure (2012)

- Servier : Heart Failure (2013)

- Abbott : MitraClip (2013)

- Menarini : nebivolol (2014)

- St Jude Medical : Heart Failure (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Brilique (2012)

- Servier : Coversyl (2012)

- Abbott Vascular : MitraClip (2012)

- Astrazeneca : Dyslipidemia (2013)

- Boston Scientific : CRT (2014)

- Servier : procoralan (2014)

- Daiichi Sankyo : Teaching course on imaging (2015)

D - Research funding (departmental or institutional).- Actelion : Pulmonary Hypertension (2013)

Landmesser Ulf A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Cardiovascular Research (2012)

- Roche Pharma : Cardiovascular Research (2012-2013)

27/08/2015




4/50

Landmesser Ulf - Amgen : Advisory Board, Speakers fee (2014-2015)

- Sanofi Aventis : Advisory Board, Speakers fee (2014-2015)

- MSD : Advisory Board, Speakers fee (2014-2015)

- Roche Pharma : Research grant, Advisory Board (2014-2015)

- Pfizer : Research grant, Speakers fee (2014-2015)

- St. Jude : Advisory Board (2015)

Mehilli Julinda A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Roche Diagnostics : Antithrombotic drugs (2012-2013)

- Lilly/Daiichi Sankyo : Antithrombotic drugs (2012-2013)

- Biotronik : PCI (2012-2013)

- Terumo Inc : PCI (2012-2013)

- Abbott Vascular : PCI (2012-2013)

- Daiichi Sankyo : Drugs (2014-2015)

- Edwards Lifesciences : Prosthesis (2014-2015)

- Terumo Inc : Stents (2014-2015)

- Abbott Vascular : Stents (2014-2015)

Mueller Christian Eugen A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Alere : Diagnostics (2012)

- Novartis : Acute Heart FAilure (2012-2013-2014-2015)

- BRAHMS GmbH : Diagnostics (2012-2013-2014-2015)

- Roche Diagnostics : Diagnostics (2012-2013-2014-2015)

- Cardiorentis : Acute Heart Failure (2013-2014-2015)

- Abbott Laboratories : Diagnostics (2013-2014-2015)

27/08/2015




5/50

Mueller Christian Eugen - BG medicine : Diagnostics (2013-2014-2015)

- BioMérieux S.A : Diagnostics (2013-2014-2015)

- Siemens : Diagnostics (2013-2014-2015)

- Bristol Myers Squibb : Anticoagulation (2014-2015)


- Daiichi Sankyo : Antiplatelet therapy (2014-2015)

- Lilly : Antiplatelet therapy (2014-2015)

- Singulex : Diagnostics (2014-2015)

- Sanofi Aventis : Lipids (2014-2015)

D - Research funding (departmental or institutional).- Medicines Company : Acuet Heart FAilure (2012)

- Swiss Heart Foundation : Diagnostics (2012)

- Beckman Coulter : Diagnostics (2012)

- Nanosphere : Diagnostics (2012)

- BRAHMS GmbH : Diagnostics (2012-2013-2014-2015)

- Abbott Laboratories : Diagnostics (2012-2013-2014-2015)

- Roche Diagnostics : Diagnostics (2012-2013-2014-2015)

- Siemens : Diagnostics (2013-2014-2015)

- Singulex : Diagnostics (2014-2015)

- BioMérieux S.A : Diagnostics (2014-2015)

- Sphingotec : Diagnostics (2014-2015)

- Astra Zeneca : Perioperative care (2014-2015)

27/08/2015




6/50

Mukherjee Debabrata C - Receipt of royalties for intellectual property.- Wolters Kluwer Publishers : Textbook of Cardiology (2012-2013)

- Informa Healthcare Publishers : Textbook of Cardiology (2012-2013)

- Informa Healthcare Publishers : Cardiac catheterization Textbook (2014-2015)

Patrono Carlo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Ticagrelor, PPI (2012)

- Bayer : Aspirin (2012-2013)

- Eli Lilly : Prasugrel (2012-2013)

- Merck Sharp & Dohme : Vorapaxar (2012-2013)

D - Research funding (departmental or institutional).- Bayer AG : Aspirin (2012-2013-2014-2015)

Roffi Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : antiplatelet therapy (2012-2013)

- Lilly : antiplatelet therapy (2012-2013)

- Astra Zeneca : antipletelet therapy (2012-2013)

- Johnson & Johnson : coronary catheters (2014)

D - Research funding (departmental or institutional).- Biosensors : devices (2012-2013-2014-2015)

- Boston Scientific : devices (2012-2013-2014-2015)

- Medtronic : devices (2012-2013-2014-2015)

- Biotronik : devices (2012-2013-2014-2015)

- Abbott Vascular : devices (2012-2013-2014-2015)

Storey Robert A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Eisai : Atopaxar (2012)

- Bristol Myers Squibb : Clopidogrel (2012)

- Sanofi Aventis : Clopidogrel/PCSK9 inhibitor/otamixaban (2012)

27/08/2015




7/50

Storey Robert - Novartis : Elinogrel (2012)

- Daiichi Sankyo : Prasugrel (2012)

- Eli Lilly : Prasugrel (2012)

- Iroko Cardio : Tirofiban (2012)

- Merck Sharp & Dohme : Vorapaxar (2012)

- Regeneron : PCSK9 inhibitor (2012-2013)

- Roche Pharma : PPAR antagonist (2012-2013)

- Accumetrics : VerifyNow device (2012-2013)

- Medscape : Antiplatelet therapy (2012-2013-2014-2015)

- Astra Zeneca : Ticagrelor (2012-2013-2014-2015)

- Sanofi Aventis : PCSK9 inhibitor/otamixaban (2013)

- The Medicines Company : Cangrelor (2014-2015)

- ThermoFisher Scientific : Diagnostics (2014-2015)

- Aspen : Fondaparinux (2014-2015)

- PlaqueTec : Thrombosis research (2014-2015)

- Correvio : Tirofiban (2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : Prasugrel (2012)

- Eli Lilly : Prasugrel (2012)

- Accumetrics : VerifyNow device (2012-2013)


D - Research funding (departmental or institutional).- Eli Lilly : Prasugrel (2012)

27/08/2015




8/50

Storey Robert - Merck Sharp & Dohme : Vorapaxar (2012)

- Accumetrics : VerifyNow (2012-2013)


Valgimigli Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Accumetrics : Platlet Function Assay (2012-2013)

- Medtronic : stent (2012-2013)

- Abbott Laboratories : stent (2012-2013)

- Abbott Vascular : stent (2012-2013)

- Cordis : stent (2012-2013)

- CID : stent (2012-2013)

- Chiesi Pharma : tirofiban (2012-2013)

- Terumo Inc : Interventional cardiology (2012-2013-2014)

- Astra Zeneca : ticagrelor (2012-2013-2014)

- Iroko Cardio : Tirofiban (2012-2013-2014)

- Alvimedical : stent (2014)

D - Research funding (departmental or institutional).- Astra Zeneca : Anti-thrombotic in ACS (2014)

- Astra Zeneca : P2Y12 inhibitor (2015)

Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosensors : Stent (2012)

- Boston Scientific : Stent (2012)

- Cordis : Stent (2012)

- Edwards Lifesciences : TAVI (2012)

- Astra Zeneca : Antiplatelet drug (2012-2013)

27/08/2015




9/50

Windecker Stephan - Eli Lilly : Antiplatelet drug (2012-2013)

- Abbott : Stent (2012-2013)

- Medtronic : Stent (2012-2013)

- Biotronik : Stent (2012-2013)


- Eli Lilly : Antiplatelet therapy (2014-2015)

- Bayer Healthcare : Antithrombotic drug (2014-2015)

- Abbott : Stent and Heartvalvetherapy (2014-2015)

- Biosensors : Stents (2014-2015)

- Boston Scientific : Stents (2014-2015)

- Medtronic : TAVI, Stent (2015)

- Edwards Lifesciences : Transcatheter heart valves (2015)

D - Research funding (departmental or institutional).- Biosensors : Stent (2012)

- Medtronic : Stent (2012)

- Cordis : Stent (2012)

- St Jude Medical : OCT (2012-2013-2014-2015)

- Biotronik : Stent (2012-2013-2014-2015)

- Abbott : Stent (2012-2014-2015)

- Medtronic : Stent and Heartvalves (2014)

- Medicines Company : Antithrombotic therapy (2014-2015)

- Johnson & Johnson : Catheters (2014-2015)

27/08/2015




10/50

Windecker Stephan - Edwards Lifesciences : Heartvalves (2014-2015)

- Boston Scientific : Stent and Heartvalves (2014-2015)

27/08/2015




11/50

Abir-Khalil Saadia A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : cardiology (2013-2014-2015)

- Pfizer : cardiology (2014-2015)

- Sanofi Aventis : cardiology (2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : cardiology (2013)

- Sanofi Aventis : cardiology (2013)

Achenbach Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013)

- Behring : Anticoagulation (2013)

- Astra Zeneca : Antiplatelet Therapy (2013)

- Abbott : Coronary Intervention (2013)

- Siemens Healthcare : CT (2013)

- Servier : Imaging (2013)

- Guerbet : Imaging (2013)

D - Research funding (departmental or institutional).- Abbott : Coronary Intervention (2013-2014)

- Siemens Healthcare : Imaging (2013-2015)

Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Böhringer Ingelheim : Anticoagulatn treatment (2013)

- Roche Diagnostics : Cardiac markers (2013)

- Orion : Heart failure (2013)

- Pfizer : Lipids (2013)

- Sanofi Aventis : Lipids (2013)

- Siemens Healthcare : Markers (2013)

27/08/2015

Guidelines on NSTE-ACS (version 2015) - Reviewers



12/50

Agewall Stefan - Astra Zeneca : Platelet inhibition (2013-2014-2015)

- Thermo Fischer Scientific : Cardiac markers (2014-2015)

Aladashvili Alexander Nothing to be declared (2013-2014-2015)

Atalar Enver Nothing to be declared (2013-2014-2015)

Averkov Oleg A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GlaxoSmithKline : Antithrombotic (2013)

- Medicines Company : Antithrombotic (2013)

- Krka Pharma : Antithrombotic (2013)

- Astra Zeneca : Antithrombotic (2013-2014)

- Boehringer-Ingelheim : Antithrombotic (2013-2014)

- Janssen-Cilag : Antithrombotic (2013-2014)

- Sanofi Aventis : Antithrombotic (2013-2014)

- Bayer Healthcare : Antithrombotic (2013-2014)

- Baxter : Esmolol (2013-2014)

- Novartis : Heart failure (2013-2014-2015)

- Portola Pharmaceuticals : Antithrombotic (2014)

- Bristol Myers Squibb : Antithrombotic (2014)

- Apex : Antithrombotic (2014)

- Sorbent : Heart failure (2014)

- Amarin : Dyslipidemia (2014-2015)

- Astra Zeneca : Ahtithrombotic (2015)

- Boehringer-Ingelheim : Ahtithrombotic (2015)

- Janssen-Cilag : Ahtithrombotic (2015)

27/08/2015




13/50

Averkov Oleg - Sanofi Aventis : Ahtithrombotic (2015)

- Bayer Healthcare : Ahtithrombotic (2015)

- Portola Pharmaceuticals : Ahtithrombotic (2015)

- Bristol Myers Squibb : Ahtithrombotic (2015)

- Apex : Ahtithrombotic (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Dyslipidemia (2013)

- Amarin : Dyslipidemia (2013-2014)

- Novartis : Heart failure (2013-2014)

- Portola Pharmaceuticals : Antithrombotic (2014)

- Sorbent : Heart failure (2014)

- Portola Pharmaceuticals : Ahtithrombotic (2015)

Badimon Lina A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : cardiovascular (2013)

- Sanofi Aventis : cardiovascular (2013)

- MSD-España : Lipids (2014)

- Sanofi Aventis : lipids (2014-2015)

- Burson Masteller : nutrition (2014-2015)

- Astra Zeneca : thrombosis (2014-2015)

D - Research funding (departmental or institutional).- Astrazeneca : thrombosis (2014-2015)

Baigent Colin D - Research funding (departmental or institutional).- Bayer : Aspirin (2014-2015)

- Merck Sharp & Dohme : Cardiovascular disease (2014-2015)

27/08/2015




14/50

Baigent Colin - Abbott : Fish oil (2014-2015)

- Novartis : LCZ-696 (2014-2015)

- Novartis : Transplantation (2014-2015)

- Pfizer : Transplantation (2014-2015)

E - Research funding (personal).- Novartis : LCZ696 (2013)

Bang Lia Evi A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Anti lipid drug (2013)

- Merck Sharp & Dohme : Anti lipid drug (2013)

- Astra Zeneca : Anti trombotic (2013)

- Amgen : Lipid lowering drug (2014)

- Astra Zeneca : Lipid lowering drug (2014)

- Merck Sharp & Dohme : Lipid lowering drug (2014)

- Amgen : Cardiovaskular (2015)

- Astra Zeneca : Cardiovaskular (2015)

- Bayer : Cardiovaskular (2015)

- Sanofi Aventis : Cardiovaskular (2015)

- Merck Sharp & Dohme : Cardiovaskular (2015)

- GSK : Cardiovaskular (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Anti lipid drug (2013)

- GlaxoSmithKline : Anti lipid drug (2013)

- Lilly : Anti lipid drug (2013)

27/08/2015




15/50

Barrabes Jose A A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Rovi : Antianginal agents (2013)

- Bayer : Anticoagulant agents (2013)

- Astra Zeneca : antiplatelet agents (2013-2014-2015)

- Menarini : Antianginal agents (2014-2015)

D - Research funding (departmental or institutional).- Astra Zeneca : Antiplatelet agents (2014-2015)

- GlaxoSmithKline : Participation in LATITUDE TIMI 60 study (losmapimod) (2015)

Baumgartner Helmut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014-2015)

- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015)

- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014-2015)

- Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015)

- Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan for PAH treatment in congenital heart disease (2013-2014-2015)





Becker David Nothing to be declared (2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Krka Pharma : Cardiology (2014-2015)

- Bayer Healthcare : Cardiology (2015)

Beishenkulov Medet Nothing to be declared (2013-2014-2015)

27/08/2015




16/50

Bolognese Leonardo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Eli Lilly, Daichhi Sankio, Abbott, Menarini, Astra : antiplatelet therapy, antianginal Rx, stents (2013-2014-2015)

D - Research funding (departmental or institutional).- Astra Zeneca : antiplatelet therapy (2013-2014-2015)

Budaj Andrzej A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : alirocumab (2013-2014-2015)

- Bristol Myers Squibb/Pfizer : apixaban (2013-2014-2015)

- Novartis : canakinumab (2013-2014-2015)

- Boehringer-Ingelheim : dabigatran (2013-2014-2015)

- GlaxoSmithKline : darapladib, losmapimod (2013-2014-2015)

- Eisai : lorcaserin (2013-2014-2015)

- Astra Zeneca : ticagrelor, dapagliflozin (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : apixaban (2013-2014-2015)

- Novartis : canakinumab (2013-2014-2015)


- GlaxoSmithKline : darapladib, losmapimod (2013-2014-2015)

- Eisai : lorcaserin (2013-2014-2015)

- Astra Zeneca : ticagrelor, dapagliflozin (2013-2014-2015)

Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- BMS/Pfizer : Apixaban (2013)

- Roche Pharma : Dalcetrapib (2013)

- Novartis : Relaxin (2013)

- Bayer Healthcare : Aspirin, rivaroxaban (2013-2014-2015)

- Sanofi Aventis : Clopidogrel (2013-2014-2015)

27/08/2015




17/50

Bueno Hector - Daiichi Sankyo : Prasugrel (2013-2014-2015)

- Eli Lilly : Prasugrel (2013-2014-2015)

- Astra Zeneca : Ticagrelor (2013-2014-2015)

- Novartis : Serelaxin (2014)

- Pfizer : Apixaban (2014-2015)

- Bristol Myers Squibb : Apixaban (2014-2015)

- Servier : ivabradine (2014-2015)

- Menarini : Ranolazine (2014-2015)

- Abbott : Absorb stent (2015)

- Novartis : Serelaxin, ACZ696 (2015)

- Ferrer Internacional : Trinomia (polypill) (2015)

D - Research funding (departmental or institutional).- Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015)

E - Research funding (personal).- Astra Zeneca : Ticagrelor (2013-2014-2015)

Bugiardini Raffaele Nothing to be declared (2013-2014-2015)

Carerj Scipione Nothing to be declared (2013-2014-2015)

Casselman Filip A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Atrial fibrillation (2013-2014-2015)

- Edwards Lifesciences : Minimally invasive cardiac surgery (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Atrial fibrillation (2013-2014-2015)

- Edwards Lifesciences : Minimally invasive cardiac surgery (2013-2014-2015)

Chilingaryan Aram Nothing to be declared (2013-2014-2015)

27/08/2015




18/50

Cuisset Thomas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medicines Company : Anticoagulant agent (2013)

- Eli Lilly : Antiplatelet (2013)

- Astra Zeneca : Antiplatelet Drug (2013)

- Daiichi Sankyo : Antiplatelet drug (2013)

- Iroko Cardio : Antiplatelet drug (2013)

- Biosensors : Device (2013)

- Boston Scientific : Device (2013)

- Terumo Inc : Device (2013)

- Abbott Vascular : Device (2013)

- Boston Scientific : DES (2014-2015)

- Biotronik : DES (2014-2015)

- Abbott Vascular : DES (2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Clopidogrel (2014-2015)

- Eli Lilly : Prasugrel (2014-2015)

D - Research funding (departmental or institutional).- Eli Lilly : Medications (2013)

- Biomatrix : DES (2014-2015)

- Europa : Education (2014-2015)

- Bayer : Rivaroxaban (2014-2015)

- Hexacath : Stent (2014-2015)

- Edwards Lifesciences : TAVI (2014-2015)

- Astra Zeneca : Ticagrelor (2014-2015)

27/08/2015




19/50

Eftychiou Christos Nothing to be declared (2013-2014-2015)

Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : Hypertension (2013-2014-2015)

Etriby Adel Mohamad Kamal

Nothing to be declared (2013-2014-2015)

Fitzsimons Donna Nothing to be declared (2013-2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : FH Tratment options (2014)

Gaemperli Oliver Nothing to be declared (2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosensors : Stents (2014)

- Biosensors : Axxess Bifurcation Stent (2015)


- Biosensors : Travel Grant to AsiaPCR 2015 (2015)

Ginghina Carmen Nothing to be declared (2013-2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- - LABORMED ALVOGEN (“Tabloul clinic al arteriopatiei periferice”) - ALFA WASSERMMAN (“Medicatia in arteriopatiile

periferice – Vessel Due”) : - LABORMED ALVOGEN (“Tabloul clinic al arteriopatiei periferice”) - ALFA WASSERMMAN (“Medicatia in arteriopatiile periferice – Vessel Due”) (2014)

Grosu Aurel Nothing to be declared (2013-2014-2015)

Gudnason Thorarinn Nothing to be declared (2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : NOAC (2014)

E - Research funding (personal).- Novartis : Heart failure (2013)

27/08/2015




20/50

Halle Martin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Merck Sharp & Dohme : diabetes, prevention (2013)

- Novartis : transplantation (2013)

- Roche Pharma : diabetes, dyslipidemia (2013-2014)

- Berlin Chemie AG : diabetes, prevention (2013-2014)

- Sanofi Aventis : diabetes (2013-2014-2015)

- Novartis : heart failure (2014-2015)

- Merck Sharp & Dohme : lipids (2014-2015)

- Pfizer : coagulation (2015)

- Daiichi Sankyo : coagulation, diabetes (2015)

- Berlin Chemie AG : diabetes (2015)

- Roche Pharma : diabetes (2015)

- Techniker Krankenkasse : health insurance company (2015)

- Abbott : lipids (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Techniker Krankenkasse Hamburg : Health Insurance Company. Monitoring of Pilot Study (2013-2014)

Hamm Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Iroko Cardio : drugs (2013)

- Roche Diagnostics : marker (2013)

- Medtronic : PCI (2013)

- Astra Zeneca : drugs (2013-2014-2015)

- Boehringer-Ingelheim : drugs (2013-2014-2015)

- Daiichi Sankyo : drugs (2013-2014-2015)

- Novartis : drugs (2013-2014-2015)

27/08/2015




21/50

Hamm Christian - Pfizer : drugs (2013-2014-2015)

- Sanofi Aventis : drugs (2013-2014-2015)

- GlaxoSmithKline : drugs (2013-2014-2015)

- Lilly : drugs (2013-2014-2015)

- Berlin Chemie AG : drugs (2013-2014-2015)

- Heart.org : drugs (2013-2014-2015)

- Bayer Healthcare : drugs (2013-2014-2015)

- Gilead : drugs (2013-2014-2015)

- Medicines Company : drugs (2013-2014-2015)

- Merck Sharp & Dohme : drugs (2013-2014-2015)

- Abbott Vascular : interventional devices (2013-2014-2015)

- BRAHMS GmbH : markers (2013-2014-2015)

- Siemens Healthcare : MRI (2013-2014-2015)

- Boston Scientific : PCI (2013-2014-2015)

- TIMI group : study advisor (2013-2014-2015)

- Roche Diagnostics : biomarker (2014-2015)

- Correvio : drugs (2014-2015)

- Medtronic : PCI, Valves (2014-2015)

- Edwards Lifesciences : Valves (2014-2015)

- Symetis SA : Valves (2014-2015)

D - Research funding (departmental or institutional).- Deutsche Forschungsgemeinschaft : experimental (2013-2014-2015)

- German Research Foundation : experimental studies (2013-2014-2015)

27/08/2015




22/50

Held Claes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astrazeneca : cardiology (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Roche Diagnostics : cardiology (2013-2014)

- Astra Zeneca : cardiology (2013-2014-2015)

- Pfizer : cardiology (2013-2014-2015)

- GlaxoSmithKline : cardiology (2013-2014-2015)

- Bristol Myers Squibb : cardiology (2013-2014-2015)

Hildick-Smith David A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott Laboratories : Advisory Board (2013-2014-2015)

- AGA : Advisory Board and proctoring (2013-2014-2015)

- Medtronic : proctor (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- W.L. Gore & associates : Advisory Board, Research (2013-2014-2015)

C - Receipt of royalties for intellectual property.- Terumo Inc : Advisory Board (2013-2014-2015)

D - Research funding (departmental or institutional).- Abbott Laboratories : stents (2013-2014-2015)

Huber Kurt A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : atorvastatin, edoxaban (2013-2014-2015)

- Medicines Company : bivalirudin; cangrelor (2013-2014-2015)

- BRAHMS GmbH : copeptin assay (2013-2014-2015)


- Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : prasugrel; abciximab (2013-2014-2015)

- Bayer : rivaroxaban (2013-2014-2015)

- Astra Zeneca : ticagrelor; rosuvastatin (2013-2014-2015)

27/08/2015




23/50

Huber Kurt - Bristol Myers Squibb / Pfizer : Apixaban (2014-2015)

- Daiichi Sankyo : edoxaban (2014-2015)

- Amgen : PCSK9-inhibition (2014-2015)

Iliodromitis Efstathios Nothing to be declared (2013-2014-2015)

James Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : coagulation inhibition (2013-2014)

- Merck Sharp & Dohme : coagulation inhibition (2013-2014)

- Medtronic : Stents and valves (2013-2014)

- Astra Zeneca : Platelet inhibition (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Eli Lilly : platelet inhibition (2013-2014)

- Medtronic : thrombus asp catheter (2013-2014)

- Terumo Inc : thrombus asp catheter (2013-2014)

- Vascular solutions : thrombus asp catheter (2013-2014)

- Astra Zeneca : platelet inhibition (2013-2014-2015)

D - Research funding (departmental or institutional).- Astra Zeneca : Anti thrombotics (2015)

Kedev Sasko A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Honaria (2013)

- Abbott Vascular : Speaker fees (2013)

- Boston Scientific : Speaker fees (2013-2014-2015)

- Meril : Speaker fees (2014)

- Medtronic : Speaker fees (2014-2015)

- Terumo Inc : Speaker fees (2015)

27/08/2015




24/50

Koning Rene Nothing to be declared (2013-2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Lilly : cardiology (2015)

- Abbott Vascular : cardiology (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Committee Member of CFCI (congres francophone Paris) : CARDIOLOGY (2015)

D - Research funding (departmental or institutional).- Biosensors : CARDIOLOGY (2015)

- Boston Scientific : CARDIOLOGY (2015)

- Biotronik : CARDIOLOGY (2015)

- Braun : CARDIOLOGY (2015)

Larsen Alf Inge Nothing to be declared (2013-2014-2015)

Latkovskis Gustavs A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Antiplatelets (2013)

- Takeda Pharmaceuticals : Cardiovascular risk (2013)

- Novo-Nordisk : Diabetes (2013)

- Servier : Hypertension (2013)

- Abbott Laboratories : lipid-lowering drugs (2013)

- GlaxoSmithKline : LPH (2013)

- Pfizer : Dyslipidemias, anticoagulants (2013-2014)

- Bayer : Anticoagulants (2013-2014-2015)

- Boehringer-Ingelheim : Anticoagulants (2013-2014-2015)

- Berlin Chemie AG : Antihypertensive agents (2013-2014-2015)

- Merck Serono : Beta blockers (2013-2014-2015)

27/08/2015




25/50

Latkovskis Gustavs - University of Latvia : Education (2013-2014-2015)

- Latvian Research Institute of Cardiology : genetics of CVD, pharmacogenetics (2013-2014-2015)

- Siemens Healthcare : hs-troponin I (2013-2014-2015)

- Astra Zeneca : lipid-lowering drugs, anti platelets (2013-2014-2015)

- Servier : Hypertension, heart rate (2014-2015)

- Latvian Association of Human Genetics : Lecture on familial hypercholesterolemia (2015)

- Mylan : Lipid lowering therapies (2015)

D - Research funding (departmental or institutional).- Latvian Council of Science : Genetics of CVD (2013)

- Latvian Council of Science : Trimethylamine N-oxide and glucose metabolism; familial hypercholesterolemia. (2015)

E - Research funding (personal).- Bayer : Anticoagulation (2013)

- Merck Serono : bisoprolol and amlodipine combination (2013-2014-2015)

- Pharma and Chemistry Competence Centre of Latvia : Statin myopathy (2014-2015)

Lewis Basil S A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Anti-diabetics (2013)

- Astra Zeneca : Antithrombotics (2013-2014-2015)

- Merck Sharp & Dohme : Anti-thrombotics (2013-2014-2015)

- Amgen : Lipidology (2013-2014-2015)

- Pfizer : Antithrombotics (2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GlaxoSmithKline : Anti-atherosclerosis (2013)

- Daiichi Sankyo : Diabetes, antithrombotics (2013)

- Eli Lilly : Heart failure (2013)

27/08/2015




26/50

Lewis Basil S - Sanofi Aventis : Lipidology (2013)

- Novartis : Heart failure (2013-2014-2015)

- Amgen : Lipidology (2013-2014-2015)

- Pfizer : Lipidology (2013-2014-2015)

- Astra Zeneca : Diabetes (2014-2015)

- Pfizer : Diabetes (2014-2015)

Lip Gregory Y H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astellas : atrial fibrillation, thrombosis (2013)

- Biotronik : atrial fibrillation (2013-2014-2015)

- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2013-2014-2015)

- Daiichi Sankyo : atrial fibrillation, thrombosis (2013-2014-2015)

- Pfizer : atrial fibrillation, thrombosis (2013-2014-2015)

- Bayer Healthcare : atrial fibrillation, thrombosis (2013-2014-2015)

- Bristol Myers Squibb : atrial fibrillation, thrombosis (2013-2014-2015)

- Medtronic : atrial fibrillation (2014-2015)

- Roche Diagnostics : anticoagulation (2015)

D - Research funding (departmental or institutional).- Bayer : atrial fibrillation, thrombosis (2013)

- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)

Magri Caroline Jane Nothing to be declared (2013-2014-2015)

Marandi Toomas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Portola Pharmaceuticals : Betrixaban, investigator (2013-2014)

- Boehringer-Ingelheim : Empagliflozin, investigator (2013-2014-2015)

- Astra Zeneca : Myocardial infarction, speaker (2013-2014-2015)

27/08/2015




27/50

Matetzky Shlomi Nothing to be declared (2013-2014-2015)

Milicic Davor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : cardiovascular drugs (2013-2014)

- Boehringer-Ingelheim : cardiovascular drugs (2013-2014)

- Pfizer : cardiovascular drugs (2013-2014)

- Sanofi Aventis : cardiovascular drugs (2013-2014)

- Bayer Healthcare : cardiovascular drugs (2013-2014)

- Krka Pharma : cardiovascular drugs (2013-2014)

- Pliva, : cardiovascular drugs (2013-2014)

- Thoratec : mechanical circulatory support (2013-2014)

- Marck Medical : mechanical circulatory support (2013-2014)

D - Research funding (departmental or institutional).- University of Zagreb : Antithrombotic drugs (2015)

E - Research funding (personal).- University of Zagreb : Platelet reactivity to antithrombotic drugs (2013-2014)

Mimoso Jorge M Vieira A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Ivabradine (2013)

- JaBA Recordati : Pitavastatine (2014)

- Bayer : Xarelto (2014)

- Boehringer-Ingelheim : Dabigatrano (2015)

- Astra Zeneca : Ticagrelor (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Ticagrelor (2013)

Mourali Mohamed Sami Nothing to be declared (2013-2014-2015)

Mussagaliyeva Aisulu A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Stable angina (2013-2014)

27/08/2015




28/50

Mussagaliyeva Aisulu B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Stable angina (2013-2014-2015)

Najafov Ruslan Nothing to be declared (2013-2014-2015)

Nedeljkovic Milan Nothing to be declared (2013-2014-2015)

Neumann Franz Josef B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antiplatelet therapy (2013-2014-2015)

- Daiichi Sankyo : Antiplatelet therapy (2013-2014-2015)

- Lilly : Antiplatelet therapy (2013-2014-2015)

- Boehringer-Ingelheim : Antithrombotic Therapy (2013-2014-2015)

- Medicines Company : Antithrombotic therapy (2013-2014-2015)

- Edwards Lifesciences : Catheter Valves (2013-2014-2015)

- Boston Scientific : Interventional Cardiology (2013-2014-2015)

- Medtronic : Interventional Cardiology (2013-2014-2015)

- Biotronik : Interventional Cardiology (2013-2014-2015)

D - Research funding (departmental or institutional).- Biotronik : Interventional Cardiology (2013-2014-2015)

- Braun : Interventional Cardiology (2013-2014-2015)

- Edwards Lifesciences : Transcatheter Valves (2013-2014-2015)

Parkhomenko Alexander A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : trimetazidin, rivaroxaban, ticagrelor (2013-2014)

- BHFZ : corvitin (2015)

- Bayer Healthcare : rivaroxaban (2015)

- Astra Zeneca : ticagrelor (2015)

- Servier : trimetazidine (2015)

27/08/2015




29/50

Parkhomenko Alexander B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : rivaroxabane (2013-2014)

C - Receipt of royalties for intellectual property.- BHFZ : corvitine (2013-2014)

D - Research funding (departmental or institutional).- European Research Foundation FP7 : biomarkers (2015)

Pereira Bruno Nothing to be declared (2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Speaker Fees (2014)

- Abbott Vascular : Speaker Fees (2014)

- Merck Sharp & Dohme : Speaker Fees (2015)

Peters Ron J G Nothing to be declared (2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : anticoagulants (2014)

- Daiichi Sankyo : antiplatelet agents (2014)

- Amgen : lipid lowering (2014)

- Sanofi Aventis : lipid lowering (2014)

- Merck Sharp & Dohme : lipid lowering (2014)

- Astrazeneca : lipid lowering (2014)

- Sanofi Aventis : alirocumab (2015)

- Amgen : evolocumab (2015)

- Astrazeneca : ticagrelor (2015)

D - Research funding (departmental or institutional).- Philips Healthcare : DirectLife activity program (2015)

- weight watchers international : weight reduction and physical fitness (2015)

Piepoli Massimo Francesco Nothing to be declared (2013-2014-2015)

27/08/2015




30/50

Pietila Mikko Juhani A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- St Jude Medical : Invasive cardiology (2013)

- Pfizer : Secondary prevention (2013)

- Astra Zeneca : Acute coronary syndromes (2013-2014-2015)

- Bayer : Prevention of thromboembolism (2013-2014-2015)

- Servier : Heart failure (2014)

- Novartis : Heart failure (2015)

Postadzhiyan Arman A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : ACS (2013-2014-2015)

- Boehringer-Ingelheim : AF (2013-2014-2015)

- Bayer : AF (2014-2015)

- Pfizer : AF (2015)

- Servier : arterial hypertension (2015)

- Merck Sharp & Dohme : arterial hypertension (2015)

- Berlin Menarini : arterial hypertension (2015)

- Sanofi Aventis : lipids (2015)

Richter Dimitrios A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : CAD (2013)

- Novartis : hypertension (2013-2014-2015)

- Abbott : Lipids (2013-2014-2015)

- Amgen : lipids (2013-2014-2015)

- Unilever : lipids (2013-2014-2015)

- Merck Sharp & Dohme : lipids (2013-2014-2015)

- Vianex : lipids (2013-2014-2015)

27/08/2015




31/50

Richter Dimitrios - Swisspharma : lipids-hypertension (2013-2014-2015)

- Astra Zeneca : lipids-thrombosis (2013-2014-2015)

- Pfizer : lipids-thrombosis (2013-2014-2015)

- Boehringer-Ingelheim : thrombosis (2013-2014-2015)

- Bayer Healthcare : Thrombosis (2013-2014-2015)

- Menarini : CAD- hypertension (2014-2015)

- Sanofi Aventis : Lipids (2014-2015)

- Lilly : Lipids (2014-2015)

- Angelini : Lipids (2014-2015)

- Galenica : Lipids (2014-2015)

- Winmedica : lipids-thrombosis (2014-2015)

- Actavis : Lipids, thrombosis (2015)

Rickli Hans A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Dabigatran (2013)

- Daiichi Sankyo : Prasugrel (2013-2014)

- Servier : Ivabradin (2013-2014-2015)

- Bayer Healthcare : Rivaroxaban (2013-2014-2015)


Rosemann Thomas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : general internal medicine (2013-2014)

- Novartis : Lecture about personalized medicine (2014)

- Menarini : Hypertension (2015)

D - Research funding (departmental or institutional).- Menarini : Hypertension (2015)

27/08/2015




32/50

Sechtem Udo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Drugs (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Berlin Chemie AG : Drugs (2013)

- Astra Zeneca : Drugs (2013-2014)

- Pfizer : Drugs (2013-2014)

- Siemens Healthcare : Drugs (2013-2014)

- Bayer Vital : Drugs (2013-2014)

- Boehringer-Ingelheim : Drugs (2013-2014-2015)

- Bayer Healthcare : Drugs (2013-2014-2015)

- Berlin Chemie AG : cath lab equipment (2014)

- Bristol Myers Squibb : Drugs (2015)

Serpytis Pranas D - Research funding (departmental or institutional).- European Research Foundation FP7 : CULPRIT-SHOCK study, National Investigator (2013-2014-2015)

Sinnaeve Peter R B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : ACS (2013)

- GlaxoSmithKline : ACS & CAD (2013)

- Abbott Vascular : PCI (2013)

- Lilly : ACS (2013-2014-2015)

- Bayer : ACS & AF (2013-2014-2015)

- Boehringer-Ingelheim : ACS & AF (2013-2014-2015)

- Merck Sharp & Dohme : CAD & ACS (2013-2014-2015)

- Duke University : trials (2013-2014-2015)

- Sanofi Aventis : trials, consultancy (2013-2014-2015)

27/08/2015




33/50

Sinnaeve Peter R - GlaxoSmithKline : ACS & CAD, trials (2014-2015)

- Astra Zeneca : ACS, trials (2014-2015)

- Novartis : trials (2014-2015)

D - Research funding (departmental or institutional).- Astra Zeneca : basic science and epidemiology (2013-2014-2015)

- Flemish Government : basic science (2014-2015)

Steg Philippe Gabriel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : Contrast agents (2013)

- Vivus : Drugs for obesity (2013-2014)

- Servier : antianginal agents (2013-2014-2015)

- Bayer : anticoagulants (2013-2014-2015)

- Astra Zeneca : antiplatelet agents (2013-2014-2015)

- Daiichi Sankyo : antiplatelet agents (2013-2014-2015)

- Boehringer-Ingelheim : antithrombotics (2013-2014-2015)

- Sanofi Aventis : antithrombotics (2013-2014-2015)

- GlaxoSmithKline : antithrombotics (2013-2014-2015)

- Medicines Company : antithrombotics (2013-2014-2015)

- Bristol Myers Squibb : antithrombotics (2013-2014-2015)

- Lilly : antithrombotics and lipid lowering drugs (2013-2014-2015)

- Amarin : Lipid compounds (2013-2014-2015)

- Medtronic : stents (2013-2014-2015)

- Regado Biosciences : Steering Committee for trial of anticoagulant (2014)

- Janssen-Cilag : antithrombotics (2015)

27/08/2015




34/50

Steg Philippe Gabriel - Novartis : consulting (2015)

- Pfizer : Events adjudication committee (2015)

- CSL Behring : lipid lowering drugs (2015)

C - Receipt of royalties for intellectual property.- Aterovax : Biomarkers (2013-2014-2015)

D - Research funding (departmental or institutional).- Sanofi Aventis : Clinical trial on lipids (2013-2014-2015)

- Servier : Registry on coronary artery disease (2013-2014-2015)

Studencan Martin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GlaxoSmithKline : Dabigatran (2013)

- MSD : Esetimibe, Inegy (2013-2014-2015)

Swanson Neil Nothing to be declared (2013)

D - Research funding (departmental or institutional).- Astra Zeneca : Antiplatelet drugs (ATLANTIC trial) (2014-2015)

- Astra Zeneca : Antiplatelet drugs (THEMIS trial) (2014-2015)

Terzic Ibrahim Nothing to be declared (2013-2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Preduktal - Investigator in ATPCI study (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sadra Medical : Odyssey study (2015)

Tsioufis Costas Nothing to be declared (2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Honoraria, Travel Expenses (2014-2015)

- Bayer : Honoraria, Travel Expenses (2014-2015)

- Boehringer-Ingelheim : Honoraria, Travel Expenses (2014-2015)

- Medtronic : Honoraria, Travel Expenses (2014-2015)

27/08/2015




35/50

Tsioufis Costas - Novartis : Honoraria, Travel Expenses (2014-2015)

- Pfizer : Honoraria, Travel Expenses (2014-2015)

- St Jude Medical : Honoraria, Travel Expenses (2014-2015)

- Sanofi Aventis : Honoraria, Travel Expenses (2014-2015)

- Menarini : Honoraria, Travel Expenses (2014-2015)

D - Research funding (departmental or institutional).- Recordati International : Funding (2014-2015)

- St Jude Medical : Renal denervation (2014-2015)

Vrints Christian Joseph Marie

Nothing to be declared (2015)

D - Research funding (departmental or institutional).- Medtronic : pacing, ICD & stents (2013-2014)

Weidinger Franz A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : Rivaroxaban (2013)

- Astra Zeneca : Ticagrelor, Saxagliptin (2013)


- Daiichi Sankyo : Edoxaban (2013-2014-2015)

- Lilly : Prasugrel (2013-2014-2015)

- Biotronik : Stents (2013-2014-2015)

- Novartis : Heart failure (2014-2015)

- Astra Zeneca : Ticagrelor (2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : Antiplatelet therapy (2013)

- Merck Sharp & Dohme : Lipid lowering (2013-2014)

- Biotronik : Drug-eluting stent (2014)

27/08/2015




36/50

Weidinger Franz - Sanofi Aventis : Lipid lowering (2014-2015)

D - Research funding (departmental or institutional).- Terumo Inc : Drug-eluting stent (2015)

Widimsky Petr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Antithrombotic agents (2013-2014)

- Servier : Antiischemic agents (2013-2014-2015)

- Astra Zeneca : Antithrombotic agents (2013-2014-2015)

- Bayer : Antithrombotic agents (2013-2014-2015)

- Boehringer-Ingelheim : Antithrombotic agents (2013-2014-2015)

- Daiichi Sankyo : Antithrombotic agents (2013-2014-2015)

- Eli Lilly : Antithrombotic agents (2013-2014-2015)

- Abbott : Stents (2013-2014-2015)

- Medtronic : Stents (2013-2014-2015)

Zamorano Gomez Jose Luis

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichii : Atrial Fib (2013)

- Merck Sharp & Dohme : Lipid Lowering (2013)

- Philips : 3D echo (2014)

- Toshiba medical imaging : fusion imaging 3D echo CT (2014)

- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)

- MSD : CV risk factors (2014-2015)

- Abbott : Lecturing (2015)

- Astra Zeneca : Lecturing (2015)

- Pfizer : Lecturing (2015)

- Sorin Group : Respicardia echo protocol (2015)

27/08/2015




37/50


B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- European Research FP7 : CV Imaging (2013)

- Servier : Imaging in ISchemic patients (2013)

- Siemens Healthcare : 3d echo software and free style echo (2014-2015)

- Toshiba medical imaging : Fusion Imaging (2015)

C - Receipt of royalties for intellectual property.- Springer : ESC Textbook of CV Imaging (2013)

D - Research funding (departmental or institutional).- Amgen : Clinical trial (2014-2015)

- Novartis : Clinical trial (2014-2015)

- Ikaria : Clinical trial (2014-2015)

27/08/2015




38/50

Aboyans Victor Nothing to be declared (2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antithrombotics (2014)

- Sanofi Aventis : Hyperlipidemia (2014)

- Boehringer-Ingelheim : Oral anticoagulation (2014)

- Pfizer/BMS alliance : Oral anticoagulation (2014)

- Novartis : Hypertension (2014-2015)

- Bayer Healthcare : Oral anticoagulation (2014-2015)

- Merck Sharp & Dohme : Antithrombotics (2015)

Achenbach Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013)

- Behring : Anticoagulation (2013)

- Astra Zeneca : Antiplatelet Therapy (2013)

- Abbott : Coronary Intervention (2013)

- Siemens Healthcare : CT (2013)

- Servier : Imaging (2013)

- Guerbet : Imaging (2013)

D - Research funding (departmental or institutional).- Abbott : Coronary Intervention (2013-2014)

- Siemens Healthcare : Imaging (2013-2015)

Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Böhringer Ingelheim : Anticoagulatn treatment (2013)

- Roche Diagnostics : Cardiac markers (2013)

- Orion : Heart failure (2013)

27/08/2015

Committee for Practice Guidelines 2014-2016 - MEMBERS



39/50

Agewall Stefan - Pfizer : Lipids (2013)

- Sanofi Aventis : Lipids (2013)

- Siemens Healthcare : Markers (2013)

- Astra Zeneca : Platelet inhibition (2013-2014-2015)

- Thermo Fischer Scientific : Cardiac markers (2014-2015)

Badimon Lina A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : cardiovascular (2013)

- Sanofi Aventis : cardiovascular (2013)

- MSD-España : Lipids (2014)

- Sanofi Aventis : lipids (2014-2015)

- Burson Masteller : nutrition (2014-2015)

- Astra Zeneca : thrombosis (2014-2015)

D - Research funding (departmental or institutional).- Astrazeneca : thrombosis (2014-2015)

Baron Esquivias Gonzalo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013-2014-2015)

- Boehringer-Ingelheim : Anticoagulation (2013-2014-2015)

- Daiichi Sankyo : Anticoagulation (2013-2014-2015)

- Pfizer : Anticoagulation (2013-2014-2015)

- Menarini : Ischemic disease (2015)

- Laboratorios Rovi : Ivabradine (2015)

D - Research funding (departmental or institutional).- Biotronik : Vasovagal syncope & Pacing (2013)

- Bayer : Anticoagulation (2015)

27/08/2015




40/50

Baumgartner Helmut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014-2015)





B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan for PAH treatment in congenital heart disease (2013-2014-2015)





Bax Jeroen Nothing to be declared (2014-2015)

D - Research funding (departmental or institutional).- Servier : Farma (2013)

- Edwards Lifesciences : Heart Valves (2013)

- GE Healthcare : Imaging (2013)

- Lantheus Inc : Imaging (2013)

- Boston Scientific : Pacing (2013)

- Medtronic : Pacing (2013)

- St Jude Medical : Pacing (2013)

- Biotronik : Pacing (2013)

Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- BMS/Pfizer : Apixaban (2013)

27/08/2015




41/50

Bueno Hector - Roche Pharma : Dalcetrapib (2013)

- Novartis : Relaxin (2013)

- Bayer Healthcare : Aspirin, rivaroxaban (2013-2014-2015)

- Sanofi Aventis : Clopidogrel (2013-2014-2015)

- Daiichi Sankyo : Prasugrel (2013-2014-2015)

- Eli Lilly : Prasugrel (2013-2014-2015)


- Novartis : Serelaxin (2014)


- Bristol Myers Squibb : Apixaban (2014-2015)

- Servier : ivabradine (2014-2015)

- Menarini : Ranolazine (2014-2015)

- Abbott : Absorb stent (2015)

- Novartis : Serelaxin, ACZ696 (2015)

- Ferrer Internacional : Trinomia (polypill) (2015)

D - Research funding (departmental or institutional).- Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015)

E - Research funding (personal).- Astra Zeneca : Ticagrelor (2013-2014-2015)

Carerj Scipione Nothing to be declared (2013-2014-2015)

Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : Hypertension (2013-2014-2015)

27/08/2015




42/50

Fitzsimons Donna Nothing to be declared (2013-2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : FH Tratment options (2014)

Gaemperli Oliver Nothing to be declared (2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosensors : Stents (2014)

- Biosensors : Axxess Bifurcation Stent (2015)


- Biosensors : Travel Grant to AsiaPCR 2015 (2015)

Kirchhof Paulus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2013)

- Boehringer-Ingelheim : cardiovascular (2013-2014-2015)

- Daiichi Sankyo : cardiovascular (2013-2014-2015)

- Medtronic : cardiovascular (2013-2014-2015)

- Pfizer : cardiovascular (2013-2014-2015)

- St Jude Medical : cardiovascular (2013-2014-2015)

- Sanofi Aventis : cardiovascular (2013-2014-2015)

- Meda pharma : cardiovascular (2013-2014-2015)

- Bristol Myers Squibb : cardiovascular (2013-2014-2015)

- Merck Sharp & Dohme : cardiovascular (2013-2014-2015)

- Medscape : cardiovascular (2014-2015)

- Bayer Healthcare : cardiovascular (2015)

- Correvio : cardiovascular (2015)

- Remedica : cardiovascular (2015)

27/08/2015




43/50

Kirchhof Paulus B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : cardiovascular (2013)

- Bayer Healthcare : cardiovascular (2013)

- Gilead : cardiovascular (2013)

- BMS / Pfizer alliance : cardiovascular (2013)

D - Research funding (departmental or institutional).- St Jude Medical : cardiovascular (2013-2014-2015)

- Sanofi Aventis : cardiovascular (2013-2014-2015)

- Meda pharma : cardiovascular (2013-2014-2015)

- Daiichi Sankyo : cardiovascular (2014-2015)

- British Heart Foundation : cardiovascular (2014-2015)

- BMS / Pfizer alliance : cardiovascular (2014-2015)

- Leducq Foundation : cardiovascular (2014-2015)

- European Union FP7 : cardiovascular (2014-2015)

- European Union horizon2020 : cardiovascular (2014-2015)

- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)

Kolh Philippe H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- B.Braun : Surgical instruments (2013-2014)

- Astra Zeneca : Antiplatelet agents (2013-2014-2015)

D - Research funding (departmental or institutional).- St Jude Medical : Cardiac valves (2013)

- Boston Scientific : Coronary stents (2013)

- Siemens Healthcare : Medical imaging (2013)

- Johnson & Johnson : Thoracoscopic devices (2013)

27/08/2015




44/50

Kolh Philippe H - Edwards Lifesciences : Cardiac valves (2013-2014-2015)

- Medtronic : Cardiac valves (2013-2014-2015)

Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Heart Failure (2013)

- Abbott : MitraClip (2013)

- Menarini : nebivolol (2014)

- St Jude Medical : Heart Failure (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astrazeneca : Dyslipidemia (2013)

- Boston Scientific : CRT (2014)

- Servier : procoralan (2014)

- Daiichi Sankyo : Teaching course on imaging (2015)

D - Research funding (departmental or institutional).- Actelion : Pulmonary Hypertension (2013)

Lip Gregory Y H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astellas : atrial fibrillation, thrombosis (2013)

- Biotronik : atrial fibrillation (2013-2014-2015)

- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2013-2014-2015)

- Daiichi Sankyo : atrial fibrillation, thrombosis (2013-2014-2015)

- Pfizer : atrial fibrillation, thrombosis (2013-2014-2015)

- Bayer Healthcare : atrial fibrillation, thrombosis (2013-2014-2015)

- Bristol Myers Squibb : atrial fibrillation, thrombosis (2013-2014-2015)

- Medtronic : atrial fibrillation (2014-2015)

- Roche Diagnostics : anticoagulation (2015)

27/08/2015




45/50

Lip Gregory Y H D - Research funding (departmental or institutional).- Bayer : atrial fibrillation, thrombosis (2013)

- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)

Nihoyannopoulos Petros Nothing to be declared (2014-2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GSK : Consultant for Imaging studies (2013)

Piepoli Massimo Francesco Nothing to be declared (2013-2014-2015)

Ponikowski Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : anticoagulant (2013)

- Bristol Myers Squibb : anticoagulant (2013)

- ROSCHE : diabetes (2013)

- Boehringer-Ingelheim : anticoagulant (2013-2014)

- Respicardia : anticoagulant (2013-2014)

- Johnson & Johnson : heart failure (2013-2014)

- Pfizer : heart failure, anticoagulant (2013-2014)

- Abbott Vascular : devices (2013-2014-2015)

- Novartis : heart failure (2013-2014-2015)

- Cardiorentis : heart failure (2013-2014-2015)

- Bayer Healthcare : heart failure (2013-2014-2015)

- Vifor Pharma ltd : heart failure (2013-2014-2015)

- CIBIEM : heart failure (2013-2014-2015)

- Servier : heart failure, coronary artery disease (2013-2014-2015)

- Amgen : heart failure, lipids (2013-2014-2015)

- MSD : lipids (2014)

27/08/2015




46/50

Ponikowski Piotr - Astra Zeneca : acute coronary syndrome (2014-2015)

- Boehringer-Ingelheim : anticoagulant, diabetes (2015)

- Respicardia : devices (2015)

- BioControl : devices (2015)

- DC Device : devices (2015)

- Celladon : heart failure (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Vifor Pharma ltd : heart failure (2014)

- MSD : lipids (2014)

- Astra Zeneca : acute coronary syndrome (2014-2015)

- Respicardia : anticoagulant (2014-2015)

- Novartis : heart failure (2014-2015)

- Cardiorentis : heart failure (2014-2015)

- Bayer Healthcare : heart failure (2014-2015)

- CIBIEM : heart failure (2014-2015)

- Servier : heart failure, coronary artery disease (2014-2015)

- Amgen : heart failure, lipids (2014-2015)

- BioControl : devices (2015)

- DC Device : devices (2015)

- Celladon : heart failure (2015)

D - Research funding (departmental or institutional).- Vifor Pharma ltd : heart failure (2013)

- Singulex : biomarkers (2015)

27/08/2015




47/50

Roffi Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : antiplatelet therapy (2013)

- Lilly : antiplatelet therapy (2013)

- Astra Zeneca : antipletelet therapy (2013)

- Johnson & Johnson : coronary catheters (2014)

D - Research funding (departmental or institutional).- Biosensors : devices (2013-2014-2015)

- Boston Scientific : devices (2013-2014-2015)

- Medtronic : devices (2013-2014-2015)

- Biotronik : devices (2013-2014-2015)

- Abbott Vascular : devices (2013-2014-2015)

Torbicki Adam A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : Pulmonary arterial hypertension (2013-2014-2015)

- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2013-2014-2015)

- Lilly : pulmonary arterial hypertension - ambrisentan (2013-2014-2015)

- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2013-2014-2015)

- Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto (2013-2014-2015)

- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : Pulmonary hypertension (2013-2014-2015)

Vaz Carneiro Antonio Nothing to be declared (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- AbbVie : Oncology (2013-2014)

Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antiplatelet drug (2013)

- Eli Lilly : Antiplatelet drug (2013)

27/08/2015




48/50

Windecker Stephan - Abbott : Stent (2013)

- Medtronic : Stent (2013)

- Biotronik : Stent (2013)


- Eli Lilly : Antiplatelet therapy (2014-2015)

- Bayer Healthcare : Antithrombotic drug (2014-2015)

- Abbott : Stent and Heartvalvetherapy (2014-2015)

- Biosensors : Stents (2014-2015)

- Boston Scientific : Stents (2014-2015)

- Medtronic : TAVI, Stent (2015)

- Edwards Lifesciences : Transcatheter heart valves (2015)

D - Research funding (departmental or institutional).- St Jude Medical : OCT (2013-2014-2015)

- Biotronik : Stent (2013-2014-2015)

- Medtronic : Stent and Heartvalves (2014)

- Medicines Company : Antithrombotic therapy (2014-2015)

- Johnson & Johnson : Catheters (2014-2015)

- Edwards Lifesciences : Heartvalves (2014-2015)

- Abbott : Stent (2014-2015)

- Boston Scientific : Stent and Heartvalves (2014-2015)


A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichii : Atrial Fib (2013)

- Merck Sharp & Dohme : Lipid Lowering (2013)

27/08/2015




49/50


- Philips : 3D echo (2014)

- Toshiba medical imaging : fusion imaging 3D echo CT (2014)

- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)

- MSD : CV risk factors (2014-2015)

- Abbott : Lecturing (2015)

- Astra Zeneca : Lecturing (2015)

- Pfizer : Lecturing (2015)

- Sorin Group : Respicardia echo protocol (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- European Research FP7 : CV Imaging (2013)

- Servier : Imaging in ISchemic patients (2013)

- Siemens Healthcare : 3d echo software and free style echo (2014-2015)

- Toshiba medical imaging : Fusion Imaging (2015)

C - Receipt of royalties for intellectual property.- Springer : ESC Textbook of CV Imaging (2013)

D - Research funding (departmental or institutional).- Amgen : Clinical trial (2014-2015)

- Novartis : Clinical trial (2014-2015)

- Ikaria : Clinical trial (2014-2015)

27/08/2015




50/50

Guidelines on NSTE-ACS (version 2015) - Task Force · Guidelines on NSTE-ACS (version 2015) - Task...

Documents

Transcript of Guidelines on NSTE-ACS (version 2015) - Task Force · Guidelines on NSTE-ACS (version 2015) - Task...